Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    600 result(s) found for: Chronic Obstructive Pulmonary Disease (COPD). Displaying page 14 of 30.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    EudraCT Number: 2017-000438-79 Sponsor Protocol Number: CCD-05993AA1-16 Start Date*: 2017-09-11
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: Open label, prospective, exploratory study to investigate the effect of inhaled CHF5993 pMDI on central and peripheral airway dimensions in COPD patients by Functional Respiratory Imaging
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015472 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-004715-37 Sponsor Protocol Number: M-34273-46 Start Date*: 2015-04-09
    Sponsor Name:AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden
    Full Title: A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005249-51 Sponsor Protocol Number: A7881013 Start Date*: 2010-05-19
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent UK
    Full Title: A PHASE 2B, PARALLEL, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE COMPARATOR AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK QD ADMINISTRATION OF PF-00610355 CRC-74...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) EE (Completed) BG (Completed) PL (Completed) DE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-000571-20 Sponsor Protocol Number: D9180C00002 Start Date*: 2020-10-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Dise...
    Medical condition: Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) HU (Completed) NL (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-004287-23 Sponsor Protocol Number: P04592 Start Date*: 2006-12-05
    Sponsor Name:Schering Plough Research Institute, a division of Schering Corporation
    Full Title: Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010821-38 Sponsor Protocol Number: EP-101-01 Start Date*: 2009-05-07
    Sponsor Name:Elevation Pharmaceuticals, Inc
    Full Title: Single-Dose, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilatory Effects of Glycopyrrolate Inhalation Solution (GIS) Using a High Efficiency Nebulizer in ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001593-42 Sponsor Protocol Number: CIDD001D2402 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24-week randomized, controlled, multicenter, open-label study to evaluate the effect of reminder notifications and motivational/adaptive messaging on treatment adherence of COPD subjects receiv...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) BE (Prematurely Ended) NL (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2017-004405-41 Sponsor Protocol Number: CLI-05993BA1-02 Start Date*: 2018-09-06
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A phase II, multicentre, randomised, double-blind, double-dummy, active-controlled, 3-way cross-over study to evaluate the efficacy of CHF 5993 administered via Dry Powder Inhaler (DPI) versus CHF ...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000884-42 Sponsor Protocol Number: 201316 Start Date*: 2014-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006378-32 Sponsor Protocol Number: PGX-ODSH-2006, Start Date*: 2007-04-03
    Sponsor Name:ParinGenix, Inc
    Full Title: An Open-Label Phase Followed by a Randomized, Double-Blind, Placebo-Controlled Phase in a Study Designed to Evaluate Intravenous 2-O, 3-O Desulfated Heparin (ODSH) in Hospitalized Subjects with Exa...
    Medical condition: Acute exacerbations of chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021782-70 Sponsor Protocol Number: COALA-HE Start Date*: 2011-06-22
    Sponsor Name:Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Full Title: Open monocentric clinical pilot study in COPD und Asthma patients to investigate static as well as dynamic ventilation, intrapulmonary ADC and pO2 using helium-3-MRI after inhalation of hyperpolar...
    Medical condition: The study is a diagnostic pilot study on COPD and Asthma patients
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001654-65 Sponsor Protocol Number: PDY16967 Start Date*: 2021-11-30
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: A Phase 2a, open label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002696-18 Sponsor Protocol Number: SUN101-303 Start Date*: 2013-12-18
    Sponsor Name:Sunovion Respiratory Development Inc.
    Full Title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment with Nebulized SUN-101 in Patients with COPD: GOLDEN-5 (Glycopyrrolate for Obstructive ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-005548-32 Sponsor Protocol Number: CCD-06001AA1-01 Start Date*: 2016-10-14
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 24-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 4 DOSES OF CHF 6001 DPI IN P...
    Medical condition: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-003347-30 Sponsor Protocol Number: CQVA149A2337 Start Date*: 2013-02-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week treatment, multi-center, randomized, double-blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate /gly...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-017380-42 Sponsor Protocol Number: M/34273/29 Start Date*: 2010-03-31
    Sponsor Name:ALMIRALL, S.A.
    Full Title: Efficacy and safety of three doses of aclidinium bromide compared to placebo and to an active comparator all administered twice daily by inhalation in patients with stable moderate and severe chron...
    Medical condition: Moderate to severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002578-23 Sponsor Protocol Number: A3971013 Start Date*: 2007-01-11
    Sponsor Name:Pfizer Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UK- 432,097 DRY POWDER FOR INHALATION IN ADULTS WITH MODERATE TO SEVERE CHRONIC...
    Medical condition: Chronic obstructive pulmonary disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005135-28 Sponsor Protocol Number: 1184.13 Start Date*: 2008-03-27
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co.KG
    Full Title: A randomised, double–blind, crossover efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/ 25 µg) Inhalation Powder in the morning (PE Capsule via tiotropium/salmeterol HandiHaler®), Ti...
    Medical condition: Patients of either sex, 40 years of age or older, and with a diagnosis of moderate to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005615-92 Sponsor Protocol Number: CQBM076X2203 Start Date*: 2013-11-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A two part, double blind, placebo controlled, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple doses of QBM076 in patients with COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) NL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000010-36 Sponsor Protocol Number: M/34273/25 Start Date*: 2007-10-18
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A multiple dose, double-blind, double-dummy, 3 period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 µg given either in...
    Medical condition: Stable moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 17 12:43:19 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA